Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
SmileDirectClub operated a direct-to-consumer teledentistry platform for clear aligner orthodontic treatment, bypassing traditional orthodontists through remote monitoring and mail-delivered aligners. The company filed for Chapter 11 bankruptcy in December 2023 and ceased operations, with the stock effectively worthless following delisting. The business model collapsed under regulatory scrutiny, clinical quality concerns, and unsustainable unit economics despite initial rapid growth.
Generated revenue by selling orthodontic treatment plans directly to consumers at 50-70% below traditional orthodontist pricing ($1,850 vs $5,000+ for Invisalign through orthodontists). The model relied on teledentistry regulations allowing remote treatment supervision, eliminating in-person orthodontist visits. Gross margins of ~70% reflected low manufacturing costs for thermoplastic aligners, but the company never achieved profitability due to massive customer acquisition costs ($400-600 per customer), high return rates (estimated 15-20%), and regulatory compliance expenses. The value proposition was price and convenience, but lacked the pricing power of Align Technology's Invisalign due to quality perception gaps and clinical outcome concerns.
Customer acquisition cost (CAC) trends and payback periods - rising CAC above $600 signaled deteriorating unit economics
Regulatory developments around teledentistry scope of practice - state dental board restrictions limited addressable market
Aligner shipment volumes and average selling price (ASP) - declining volumes below 100K quarterly shipments indicated demand weakness
Clinical outcome data and customer satisfaction scores - negative reviews and treatment failure rates drove brand damage
Liquidity position and debt covenant compliance - cash burn of $50M+ quarterly raised going concern risks
Regulatory prohibition risk - Multiple state dental boards challenged the teledentistry model as practicing dentistry without adequate supervision, with California and Georgia implementing restrictions that eliminated those markets
Clinical efficacy concerns - Peer-reviewed studies and American Association of Orthodontists raised questions about treatment outcomes for complex cases without in-person supervision, creating liability exposure and brand damage
Reimbursement exclusion - Dental insurance plans largely excluded direct-to-consumer aligners from coverage, limiting addressable market to cash-pay customers
Align Technology (Invisalign) market dominance - 90%+ clear aligner market share with superior brand equity, clinical track record, and orthodontist network created insurmountable competitive moat
Byte and Candid (competitor DTC aligner companies) price competition - Commoditization of DTC aligners drove price wars that compressed margins below sustainable levels
Traditional orthodontists offering in-house clear aligners - Incumbents adopted competitive pricing while maintaining clinical supervision advantage
Insolvency and bankruptcy - Company filed Chapter 11 in December 2023 with $900M+ liabilities against minimal recoverable assets, resulting in total equity wipeout
Debt covenant violations - 7.83x debt/equity ratio and negative cash flow triggered covenant breaches that accelerated bankruptcy timeline
Working capital deficiency - Despite 2.55x current ratio, the company burned through cash reserves within 6-9 months without additional financing
high - Clear aligners are elective cosmetic procedures with average $1,850-2,050 out-of-pocket cost, making demand highly sensitive to discretionary income and consumer confidence. During economic downturns, consumers defer elective dental spending. The target demographic (18-35 year olds seeking cosmetic improvement) exhibits income volatility and reduced spending during recessions. Estimated 60-70% correlation between discretionary healthcare spending and consumer sentiment indices.
Rising interest rates negatively impacted the business through multiple channels: (1) increased cost of debt service on $700M+ debt load with 7.83x debt/equity ratio, (2) reduced consumer willingness to finance elective purchases through payment plans, (3) higher discount rates compressing valuation multiples for unprofitable growth companies. The company's negative cash flow made it dependent on capital markets access, which contracted sharply as rates rose in 2022-2023.
Critical - The company's survival depended on credit availability given -$200M annual cash burn. Tightening credit conditions in 2023 eliminated refinancing options for the debt-heavy balance sheet. Additionally, ~30-40% of customers used financing options (Affirm, internal payment plans), making credit availability to end consumers a demand driver. Rising consumer credit delinquencies reduced financing approval rates and treatment plan conversions.
momentum/speculative - The stock attracted retail momentum traders during the 2019-2021 period based on disruptive healthcare narrative and rapid revenue growth. As fundamentals deteriorated, only distressed/bankruptcy investors remained. The -89.7% one-year return and -93.1% three-month return reflected complete loss of institutional support. High short interest (often 30-40% of float) indicated professional investors betting against the business model.
extreme - Historical beta exceeded 2.5x during operational period. Stock exhibited 10-20% daily moves on regulatory news, earnings misses, or liquidity concerns. The -93.1% quarterly decline represents terminal volatility associated with bankruptcy proceedings. Options market implied volatility consistently exceeded 150%, reflecting binary outcome risk.
